In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on IN8bio (INAB – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $1.15.
According to TipRanks, Ramakanth is an analyst with an average return of -20.5% and a 23.02% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Affimed, Vor Biopharma, and ImmunoGen.
Currently, the analyst consensus on IN8bio is a Strong Buy with an average price target of $11.33, which is an 885.22% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.95 and a one-year low of $1.02. Currently, IN8bio has an average volume of 261.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Read More on INAB:
